Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maximizing clinical benefit with trastuzumab.

Richard Bell1, Shail Verma, Michael Untch

  • 1Andrew Love Cancer Centre, Greelong Hospital, Victoria, Australia.

Seminars in Oncology
|October 19, 2004
PubMed
Summary

Trastuzumab, an effective treatment for HER2-positive breast cancer, shows improved outcomes when combined with endocrine therapy or chemotherapy. Continued use beyond disease progression is also a feasible and beneficial strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mammographic surveillance in breast cancer patients aged 50 years or older: a synopsis of the Mammo-50 RCT.

Health technology assessment (Winchester, England)·2026
Same author

Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2).

NPJ breast cancer·2026
Same author

The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial.

Journal of the National Cancer Institute·2026
Same author

Protocol for the PROSECCA study: a new approach for predicting radiotherapy outcome using artificial intelligence and electronic population-based healthcare data.

BMJ open·2026
Same author

Understanding Educator Perceptions in Assessment of Kindergarten Children's Development.

Early childhood education journal·2026
Same author

Molecular and Clinical Analyses of Gene Fusions Identify Therapeutic Targets in Paired Primary and Metastatic Breast Cancer from the AURORA Program (BIG 14-01).

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Optimizing breast cancer patient management involves considering hormone receptor and HER2 status.
  • Trastuzumab (Herceptin) is a key therapeutic agent for HER2-positive metastatic breast cancer.

Purpose of the Study:

  • To review the efficacy and feasibility of trastuzumab-based treatment strategies in HER2-positive metastatic breast cancer.
  • To explore combination therapies involving trastuzumab and its role in different clinical scenarios.

Main Methods:

  • Review of randomized clinical trials and retrospective data on trastuzumab efficacy.
  • Analysis of trastuzumab in combination with endocrine therapy, chemotherapy, and as a single agent.
  • Evaluation of trastuzumab use in first-line therapy and beyond disease progression.

Related Experiment Videos

Main Results:

  • Trastuzumab combined with endocrine therapy is feasible for less aggressive estrogen receptor/HER2-positive disease.
  • Trastuzumab plus chemotherapy significantly improves survival and quality of life in aggressive HER2-positive breast cancer.
  • Trastuzumab demonstrates single-agent activity and is effective when continued beyond progression.

Conclusions:

  • Trastuzumab-based regimens are effective for HER2-positive metastatic breast cancer, offering improved outcomes with manageable toxicity.
  • Combination with endocrine therapy or chemotherapy, and continuation beyond progression, represent valuable treatment strategies.